Nanoparticle Photosensitizer Targets Liver Cancer Cells with NIR Light Precision
Lactose-coated BODIPY nanoparticles home in on liver tumor receptors and destroy cancer cells with near-infrared light at nanomolar doses.
Summary
Researchers designed four lactose-coated, thiophene-fused BODIPY nanoparticles that selectively target liver cancer cells via asialoglycoprotein receptors. The lead compound, PBrTB, self-assembled into ~30 nm nanoparticles, absorbed NIR light strongly at 674 nm, and generated singlet oxygen with a quantum yield of 0.47. In hepatocellular carcinoma cell lines (Huh-7 and Hep3B), PBrTB achieved IC50 values below 76 nM under light activation while remaining non-toxic in the dark. Lactose surface functionalization drove receptor-mediated cellular uptake, explaining the superior performance over non-functionalized analogues. These results position PBrTB as a promising single-component theragnostic agent combining NIR imaging and photodynamic therapy for liver cancer.
Detailed Summary
Hepatocellular carcinoma (HCC) is among the deadliest and most treatment-resistant cancers globally, creating urgent demand for targeted therapies with minimal systemic toxicity. Photodynamic therapy (PDT) offers a light-activated, tumor-localized approach, but its effectiveness depends on photosensitizers that absorb in the tissue-penetrant near-infrared (NIR) window and accumulate selectively in tumor cells.
This study synthesized and characterized four NIR photosensitizers built on a thiophene-fused BODIPY scaffold conjugated with lactose, a sugar that binds asialoglycoprotein (ASGP) receptors overexpressed on hepatocytes and HCC cells. Bromination at different positions of the BODIPY core or terminal thiophene rings produced structural variants (PHTB, PBrTB, THTB, TBrTB) to explore structure-activity relationships.
All four compounds self-assembled into stable, uniform nanoparticles (~30 nm) in aqueous solution through hydrophobic-hydrophilic interactions between the BODIPY core and lactose shell. NIR absorption ranged from 640–674 nm across derivatives. The brominated core variant PBrTB stood out with the highest singlet oxygen quantum yield (ΦΔ = 0.47) and the most potent light-induced cytotoxicity, with IC50 values of 75.8 nM (Huh-7) and 66.4 nM (Hep3B). Other derivatives exceeded 250 nM IC50, underscoring the importance of bromination position. PHTB showed notable fluorescence and imaging potential but inferior PDT efficacy.
Cellular uptake and reactive oxygen species generation were substantially higher for PHTB and PBrTB than for the terminal-thiophene variants, strongly implicating ASGP receptor-mediated endocytosis driven by lactose as the delivery mechanism.
These findings establish PBrTB as a single-component theragnostic platform combining tumor-targeted delivery, NIR fluorescence imaging, and highly efficient PDT. Pre-clinical animal studies and toxicity profiling remain necessary before clinical translation can be considered.
Key Findings
- PBrTB nanoparticles achieved IC50 values of 75.8 nM and 66.4 nM in two HCC cell lines under NIR light.
- Singlet oxygen quantum yield of PBrTB reached 0.47, the highest among the four BODIPY derivatives tested.
- Lactose surface functionalization enabled ASGP receptor-mediated uptake, markedly boosting intracellular delivery in liver cancer cells.
- All four compounds self-assembled into uniform ~30 nm nanoparticles with strong NIR absorption (640–674 nm).
- Bromination position critically determined PDT potency; core bromination outperformed terminal thiophene bromination.
Methodology
Four thiophene-fused BODIPY photosensitizers were synthesized with lactose targeting moieties and characterized for optical properties, nanoparticle formation, and singlet oxygen generation. In vitro cytotoxicity was assessed in Huh-7 and Hep3B HCC cell lines under light and dark conditions. Cellular uptake and reactive oxygen species production were measured to evaluate receptor-mediated delivery.
Study Limitations
The study is limited to in vitro cell line experiments; in vivo pharmacokinetics, biodistribution, and efficacy data are absent. Long-term dark toxicity, immune response, and metabolic fate of the nanoparticles were not evaluated. Generalizability to primary patient-derived HCC cells or heterogeneous tumor microenvironments remains untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: